A preventive treatment for dementia may proceed to clinical trials after successful animal testing, say researchers. The research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the research added.
The study, published in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020 with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in Australia.
The researchers tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Australian lab.
The possible new therapies were tested in bigenic mice with mix Aï¿½ and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” said the study lead authors Professor Anahit Ghochikyan and Mathew Blurton-Jones.
Professor Petrovsky said the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based Aï¿½/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of Aï¿½/tau molecules and delay Alzheimer’s disease progression in a the rising number of people around the world,” Petrovsky added.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early Alzheimer’s disease as measured by primary and secondary endpoints.